GSK : New data at ASCO showcases the transformational potent

DREAMM-8 results for Blenrep in multiple myeloma featured in a late-breaking presentation and ASCO's Press Programme


Updated results from a supported...

Related Keywords

China , United Kingdom , Macau , United States , Hong Kong , Taiwan , Japan , Chicago , Illinois , Japanese , Chinese , American , Hansoh Pharma , Belantamab Mafodotin , Drug Administration , American Society Of Clinical Oncology , Biowa Inc , Kyowa Kirin Group , Anaptysbio Inc , European Commission , Memorial Sloan Kettering Cancer Center , Regulatory Agency , Japanese Society Of Medical Oncology Annual Meetings , Seagen Inc , Ivy Brain Tumor Center , Tesaro Inc , Clinical Oncology , Annual Meeting , Memorial Sloan Kettering Cancer , Medical Oncology Annual , Ivy Brain Tumor , Science Symposium , Myelofibrosis Symptom Assessment Form , Kyowa Kirin , Great Britain , Blenrep United Kingdom Summary , About Jemperli , Biologics License Application , Breakthrough Therapy , Priority Review , Important Information ,